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Abstract: 
IL-33 is a member of the IL-1 family of cytokines. IL-33 is predominantly located within the nucleus 
of cells where it plays a role in gene regulation. Given the right combination of signals and cellular 
damage, stored IL-33 is released from the cell where it can interact with its receptor ST2, triggering 
danger-associated responses and act as a cellular “alarmin”. Whilst IL-33/ST2 signalling has been 
shown to induce potent pro-inflammatory responses that can be detrimental in certain disease states, a 
dichotomous, protective role of IL-33 in promoting wound healing has also emerged in multiple 
tissues types. This review will explore the current literature concerning this homeostatic role of IL-
33/ST2 in tissue repair and also review its role in uncontrolled wound responses as seen in both 
fibrosis and tumorigenesis.  
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Introduction: IL-33/ST2 –  an „Alarmin‟ function in tissue damage  
Wound healing, whether initiated by trauma, microbes or foreign materials, is a normal homeostatic 
process required for the resolution of tissue damage. It comprises multiple consecutive, overlapping 
phases including inflammation, epithelialization, angiogenesis and matrix deposition. A critical aspect 
of tissue repair is the deposition of key connective tissue proteins, however in situations of chronic 
inflammation, impaired tissue repair mechanisms, including continuous myofibroblast differentiation 
and dysregulated collagen deposition can lead to fibrosis and impaired organ function [1]. IL-1 family 
members cytokines (notably IL-1 and IL-18) are already implicated in the regulation of wound 
healing and tissue repair [2]. Herein we examine the role of a more recently described member of the 
IL-1 family, IL-33 and its receptor ST2L, in tissue repair highlighting its role in several of the 
mechanisms underpinning wound repair fibrosis and tumorigenesis. 
Biological Properties of the IL-33/ST2 axis 
IL-33 
In 2005, IL-33 was identified as a member of the IL-1 family of cytokines [3]. The IL-33 N-terminus 
includes a nuclear localization signal and a homeodomain-like helix-turn helix DNA-binding domain 
as well as a chromatin-binding domain [4]. IL-33 mRNA is expressed in many organs - high levels of 
IL-33 mRNA are detectable in stomach, lung, spinal cord, brain and skin. It is expressed by a diverse 
range of cells with strongest expression observed in non-haematopoietic cells including endothelial 
cells, epithelial cells, keratinocytes, fibroblasts, fibrocytes and smooth muscle cells [5, 6]. Lower 
expression is reported in some activated leukocytes especially innate immune cells e.g. mast cells, 
macrophages and DCs. IL-33 can be induced by a variety of immune stimuli, for example pro-
inflammatory TLR ligands, cytokines and immune complexes [7] [8]. Different IL-33 splice variants 
have been observed in human tissues. Moreover, IL-33 is generated as a precursor and as a full-length 
protein, the latter being bioactive, similar to IL-1α [9]. Unlike other IL-1 family members, IL-33 is 
deactivated by cleavage with caspase-3 or -7. Processing by these apoptotic caspases results in 
inactive fragments [10] [11] [12].  
In terms of subcellular localisation, under homeostatic conditions, IL-33 is predominantly located in 
the nucleus of the cell [9]. Nuclear IL-33 regulates gene expression in numerous ways. Nuclear IL-33 
binds to histones and regulates chromatin structure and by default, gene expression [4] [13].  IL-33 
has also been reported to activate histone deacetylase-3 (HDAC3) activity, indicating a potential role 
for IL-33 in modulating epigenetic regulation [14]. Nuclear IL-33 has been reported to directly bind to 
NF-κB, suppressing NF-B regulated gene expression [15]. However, upon cellular damage, such as 
necrosis, IL-33 is quickly released from the nucleus and exported from the cell leading to its 
definition as an “alarmin” and also to its categorisation as a danger-associated molecular pattern 
(DAMP).  As IL-33 lacks a traditional signal sequence, it seems that cell death by either necrosis or 
necroptosis may be the predominant mechanisms by which IL-33 is liberated to the extracellular 
space [16]. This release of IL-33 from the cell facilitates its interaction with its cognate receptor ST2 
and the subsequent initiation of signalling cascades. Localisation of IL-33 is tightly regulated. Recent 
studies utilising a murine transgenic model in which the nuclear localisation of IL-33 was abolished, 
demonstrate that such mice succumb to lethal inflammation characterised by eosinophil-dominated 
immune cell infiltration of multiple organs [17], highlighting the highly pro-inflammatory role of 
extracellular IL-33. 
The IL-33 Receptor – ST2 
The IL-33 receptor (ST2) was first described in advance of the detection of IL-33 hence the 
potentially confusing terminology. Suppression of tumourigenicity 2 (ST2), also known as T1, DER4 
and FIT-1, was originally cloned as an oncogene-induced gene from murine fibroblasts.  A second 
similar ST2 mRNA transcript was also detected and predicted to code for a receptor, now known as 
the transmembrane bound ST2L receptor [9]. The originally identified protein is now known to be a 
secreted soluble form or “decoy receptor” of ST2, termed sST2. Both of these proteins contain three 
identical Ig extracellular domains, although sST2 lacks the transmembrane sequence it contains an 
additional 9 amino acids at the C terminus. Both ST2 isoforms are members of the Ig superfamily and 
ST2L specifically belongs to the Toll/IL-1R (TIR) superfamily, as it shows ~29% homology to the 
IL-1R, and contains the three distinctive extracellular Ig domains and homology to the intracellular 
domain of IL-1R1 [18]. Furthermore, a third variant isoform, termed ST2V, has also been identified 
[19] (Figure1). 
Human and murine ST2 genes contain two promoters, a distal and a proximal promoter. Both ST2L 
and sST2 isoforms can be transcribed from either promoter with promoter usage governed by the cell 
type. For example, while both the human leukaemic cell line, UT-7 and mast cells can transcribe ST2 
isotypes using either the distal or proximal promoter, the distal promoter is predominantly used in this 
cell line for expression of both sST2 and ST2L [20]. Conversely, almost all transcription is initiated 
from the proximal promoter in fibroblasts [21].  Unlike other IL-1 family members, there is no known 
antagonistic ligand for ST2.  High levels of sST2 and ST2L mRNA are expressed by the kidney, lung, 
placenta, and stomach. In humans, ST2L expression is higher in the spleen, heart, testis and colon 
than sST2, while the brain and liver express higher levels of sST2, than ST2L [22]. Many endothelial 
cells from lung, bronchus, coronary artery and umbilical cord express both ST2L and sST2 mRNA 
[23]. ST2L is strongly expressed on the surface of fibroblasts and hematopoietic cells such as T helper 
type 2 (Th2) lymphocytes, ILC2s and mast cells [24, 25]. Whilst not found constitutively expressed 
on Th1 cells and several other immune populations, some recent reports indicate that expression of 
ST2 can be induced in Th1 [26] and CD8+ T cells [27].   
IL-33/ST2 signalling 
IL-33 has two mechanisms of action. Firstly, as a nuclear factor binding directly to chromatin in the 
nucleus, discussed previously, and secondly as a cytokine binding to ST2L. Biologically active full 
length IL-33 can be released in the extracellular space after cell damage or mechanical injury [10] 
whereas nuclear IL-33 is passively released upon cell death. [6]. Both of these mechanisms of cellular 
release facilitate the interaction of IL-33 with its receptor ST2.  Upon binding of the extracellular IL-
33 to ST2L; the receptor undergoes conformational change, which enables the recruitment of IL-1 
Receptor Accessory Protein (IL-1RAcP). Heterodimerization of the two transmembrane molecules 
brings the two intracellular TIR domains together, and successive receptor adaptor proteins are 
recruited through protein-protein interactions. Once the IL-33/ST2L receptor complex is established 
the signal is transmitted by the MyD88-IRAK1/4-TRAF6 signalling pathway with resulting 
degradation of the inhibitory protein IB and subsequent activation of the NFB transcription factor 
[28]. MAP kinases, p38, JNK and ERK are also activated with activation of downstream transcription 
factors such as AP-1 (Figure 1). Activation of these transcription factors enables transcription of 
cytokines and chemokines in a cell-type restricted manner. For example activation of this pathway in 
Th2 cells leads to production of Th2 cytokines (i.e. IL-4, IL-5, IL-13) [3] whereas in epithelial cells, 
ST2 activation by IL-33 results predominantly in chemokine activation [29]. Multiple self-activated 
down-regulatory mechanisms of this pathway exist. Activation of ST2L by IL-33 results in activation 
of focal adhesion kinase (FAK) and glycogen synthase kinas 3β (GSK-3β) [30].  Once activated, 
GSK-3β binds to and phosphorylates ST2L resulting in the swift internalization of ST2L. Once 
internalized ST2L is polyubiquitinated by the E3 ubiquitin ligase FBXL19 and subsequently degraded 
by the proteasome [31]. As sST2 functions as a decoy receptor for IL-33 it negatively regulates ST2 
signalling by sequestering IL-33 and has been shown to down regulate Th2 cell-mediated 
immunologic responses [32]. 
Epithelial barrier repair: A role for IL-33 in mucosal wound healing 
Mammalian barrier surfaces including skin, lung and gastrointestinal tract are exposed to a plethora of 
potentially harmful agents deriving from external sources such as microbial or environmental as well 
as from intrinsic physical damage. The ability of these tissues to initiate effective repair processes is 
critical for their role in host defence. An absence of, or ineffective, wound healing and tissue repair 
processes can lead to chronic inflammatory states and the development of fibrotic disease. IL-33 is 
constitutively expressed by tissues involved in the maintenance of mechanical barriers, including 
keratinocytes, lung and gut epithelial cells, fibroblasts, fibrocytes and smooth muscle cells [33]. 
Emerging evidence is supportive of a critical role for the IL-33/ST2 axis in the initiation and 
maintenance of wound healing responses at these surfaces; a role that is somewhat divergent to its 
well-characterised function in promoting especially type II inflammatory responses.  We will now 
consider the diverse wound repair properties of IL-33 across a range of tissues. 
IL-33 in intestinal wound healing 
The original report identifying IL-33 in 2005 described a putative role in epithelial repair, as IL-33 
stimulation was shown to promote both epithelial proliferation and mucus production [33]. 
Subsequent human studies examining expression of both IL-33 and the different isoforms of ST2 
showed that both IL-33 mRNA and protein were found to be up regulated in inflamed UC and CD 
[34], [35], while other reports describe IL-33 to be only up regulated in UC [36].  In particular, IL-33 
was found to be increased in ulceration associated myofibroblasts in inflamed UC, although this was 
not observed in Crohns disease [37]. As the epithelium becomes damaged and mucosal lesions form 
in severe UC, IL-33 becomes increased in myofibroblasts indicating a potential involvement of IL-33 
in wound healing in intestinal tissues[38].  
Murine models, however, have revealed complex roles for IL-33 and ST2 in intestinal disease [39]. 
Similar to the changes seen in humans, increased expression of IL-33 was observed in the colons of 
mice challenged by both the trinitobenzene sulphonic acid (TNBS) and the dextran sodium sulphate 
(DSS) models [40]. Whilst certain murine models implicate a pro-inflammatory, pathogenic role for 
the IL-33/ST2 signalling axis in intestinal disease, several studies have shown that this signalling axis 
can promote a homeostatic wound healing response in the intestinal epithelium. These divergent roles 
are dependent on whether the acute or chronic inflammatory state is investigated.  Whilst mice 
deficient in ST2 demonstrate improved symptoms and reduced intestinal inflammation in the early 
stage of DSS colitis [41], a delay in the resolution of DSS dependent tissue damage in IL-33-/- mice 
was observed [42]. This dichotomous role of IL-33 in acute versus chronic IBD was also 
demonstrated using a different model, as whilst injection of IL-33 aggravated DSS-induced acute 
colitis [43], it alleviated DSS-induced chronic colitis [44-46]. Indeed, in the study of Duan et al, 
utilising the TNBS model of colitis and treatment with recombinant IL-33, it was noted that IL-33 
promotes the induction of Type 2 II cytokines and upregulated expression of FoxP3
+
 cells. In 
addition, the protective effect of IL-33 was diminished after depletion of T-regulatory (Treg) cells 
[46], which are known to facilitate wound healing [47]. Further evidence supporting a role of IL-33 in 
promoting intestinal Treg function has been provided. The IL-33 receptor ST2 is preferentially 
expressed on colonic Tregs with IL-33 signalling leading to Treg accumulation and maintenance in 
inflamed intestinal tissues. Importantly, IL-23, a potent pro-inflammatory cytokine which contributes 
to the pathogenesis if IBD, inhibits the ability of IL-33 to activate intestinal Treg [48].  In contrast IL-
33 has, also been shown to negatively regulate wound healing with both genetic ablation of ST2 and 
treatment with an ST2 blocking antibody shown to enhance wound healing. In this study, 
administration of IL-33 impaired epithelial barrier permeability both in vitro and in vivo [40].   
Whilst these lines of evidence, using the chronic model of DSS colitis, demonstrate a role for IL-33 in 
intestinal wound healing there is a relative paucity of mechanistic data associated with its role in 
epithelial repair and restoration.  IL-33 has been shown to directly affect epithelial barrier function as 
stimulation of T84 monolayers increase transepithelial resistance in an ERK-dependant manner [49].  
Hofmann et al demonstrated that IL-33-induced neutrophil influx during chronic intestinal 
inflammation was able to reduce the translocation of pathogenic bacteria across the damaged 
epithelium [45]. This reduction in bacterial load and concomitant reduction in inflammation may, 
therefore, indirectly facilitate epithelial repair.  More recently, evidence that the role of IL-33 in 
intestinal epithelial repair may be linked to its effect on group 2 innate lymphoid cells (ILC2) has 
been demonstrated. In recent years it has become evident that ILC2s express high levels of ST2 and 
are critical cellular targets of IL-33 in consequence [50]. IL-33 stimulation of ILC2 causes induction 
of high levels of IL-4, IL-5, IL-9 and IL-13, GM-CSF and amphiregulin (AREG) expression, 
promoting eosinophil expansion, mast cell recruitment and macrophage polarisation. High levels of 
amphiregulin can aid in rebuilding the intestinal barrier by stimulating growth of new epithelial cells 
and creating a protective layer of mucus that repels future attacks [51]. In the DSS model of intestinal 
colitis/intestinal repair, stimulation with IL-33 induces and activates AREG-producing ILC2s, 
resulting in restoration of epithelial barrier function and maintenance of tissue homeostasis [51].  
Given the dual roles of IL-33 in either promoting intestinal disease or in promoting intestinal wound 
healing, greater insight into the mechanistic basis underlying these is necessary to fully comprehend 
the function of IL-33/ST2 in intestinal health and disease.  
IL-33 in cutaneous wound healing 
In recent years, IL-33 has emerged as a key player in several dermatological diseases including 
psoriasis, atopic dermatitis and contact allergy [52, 53]. Recent attention has focussed on exploring 
the role of both IL-33 and ST2 in cutaneous wound healing. One of the first pieces of evidence in this 
field was shown by Sponheim et al who had previously identified recruitment of IL-33 positive 
fibroblasts and myofibroblasts to granulation tissue in the intestine [37]. In order to explore whether 
these may play a functional role in wound healing in organs other than the intestine, they investigated 
the role of these in a rat skin wound healing assay. Massive recruitment of cells with strong 
expression of IL-33 was observed in healing skin wounds in a rat model as early as 24h after 
wounding. These authors also observed activation of scattered tissue resident IL-33+, PDGFR+, 
SMA+ fibroblast-like cells at the site of wounding pointing to a role of these cells in mucosal healing 
and wound repair. Both mRNA and protein levels of IL-33 were also seen to be elevated in a murine 
model of cutaneous wound healing with the administration of exogenous IL-33 seen to accelerate 
wound healing and re-epithelialisation in the same model. The number of F480+, CD206+ cells was 
increased at the site of wounding in the IL-33 treated mice, suggesting that IL-33 promotes the 
development and/or recruitment of alternatively activated macrophages during wound healing [54]. 
These authors also utilised a murine model of Staphylococcus aureus-infected wound healing and 
demonstrated that exogenous administration of IL-33 inhibited MRSA-colonisation, whilst 
accelerating wound healing. It was noted that IL-33 administration promoted the proliferation of 
neutrophils and also of the chemokine receptor CXCR2, thereby facilitating neutrophil recruitment to 
the site of infection. In both these models an upregulation of both fibronectin and collagen IIIa was 
noted following IL-33 administration, indicating a role for IL-33 on matrix synthesis and re-
epitheliatisation  [54]. A direct link between ST2 and cutaneous wound healing has also been shown 
using standard skin wound healing models in ST2 knockout mice. Absence of ST2 results in impaired 
wound healing with reduced numbers of Ly6clo MHCII hi pro-repair macrophages observed within the 
wounds. Examination of expression of the pan-endothelial marker CD31, as a marker of angiogenesis, 
revealed a nearly 50% decrease in angiogenesis in the absence of ST2 within the granulation tissue 5 
days after wounding. Additionally, these studies highlight direct effects of IL-33 signaling on matrix 
synthesis, with reduced Col3 being apparent in St2−/− mice, whilst IL-33 treatment of wild type mice 
increased Col3 [54]. Although it seems from these reports that IL-33 signalling at the site of 
cutaneous damage may facilitate the transition of macrophages from a pro-inflammatory to a pro-
repair phenotype thereby promoting dermal wound healing, the underlying mechanism for IL-33 in 
skin wound healing remains unclear. Given the interesting observation that IL-33 expression both 
varies at a basal level and is also differentially regulated between mouse and human keratinocytes [8], 
it is clear that more detailed studies need to be performed on human tissues and human cell lines to 
fully elucidate the role of IL-33 in cutaneous wound healing in humans. 
Lessons from overuse – IL-33 and early tissue insult 
Tendinopathy is a term used to describe a complex multi-faceted pathology most commonly 
associated with overuse injury of the tendon [55]. Tendons are sites of high mechanical stressing with 
the resident stromal cells (tenocytes) and the associated extracellular matrix undergoing microtrauma 
form persistent use [56]. Importantly type III collagen is produced in the initial phases of tendon 
damage [57] as a conserved mechanism to provide a rapid 'patch' to the area of damage. Type III is 
laid down in a haphazard fashion contributing to the irregular alignment seen microscopically as well 
as translating to inferior biomechanical strength in damaged tendon [58]. Increasing evidence has 
shown that inflammatory mechanisms and the innate immune system are activated within the tendon 
matrix microenvironment during tissue injury and dysregulated homeostasis [59] [60]. Based on 
previous observations that IL-33 may directly regulate tissue remodelling, this model system was 
utilised in human and rodent disease to explore the potential role of the IL-33/ST2 axis in early tissue 
insult and the possible interactions between inflammation and matrix remodelling. IL-33/ST2/IL-
1RAcP message and protein expression was significantly increased in early human tendinopathy 
compared to both established tendinopathy and normal tendon suggesting that early „stressed‟ tendon 
had an IL-33 alarmin phenotype which may account for the associated matrix changes in collagen I/III 
ratio associated with disease [61]. Utilising in vitro human tenocyte cultures the addition of 
exogenous IL-33 resulted in increased expression of type I but particularly type III collagen 
mRNA/protein in keeping with animal studies on cutaneous wound healing. IL-33-induced collagen 
expression was abrogated by ERK and NFκB inhibition. rhIL-33 also significantly elevated the 
production of IL-6, IL-8 and CCL-2, which was abrogated by NF-κB inhibition suggesting that IL-33 
operates in tenocytes via its canonical IL-1R signaling pathway[61].  
This work was expanded to include an in vivo patellar tendon injury model [62]to understand the 
molecular events implicating IL-33 in a tissue injury model. IL-33 mRNA and protein were elevated 
in early post tendon injury (days 1&3 of 21 day model) in WT mice. This was significantly reduced in 
injured ST2−/− mice, suggesting autocrine regulation. No significant changes in either IL-33 or ST2 
transcript were found in WT mice at days 7 or 21 post injury, or for IL-33 expression in ST2−/− mice, 
suggesting that the impact of IL-33 expression is manifest early, in keeping with „alarmin‟ type 
activity in tendon injury/repair. Analysis of collagen kinetics revealed significantly greater expression 
of collagen 3 at all time points post injury in WT mice compared with uninjured controls or injured 
ST2−/− mice. Importantly, injury of WT mice tendons resulted in a significant decrease in 
biomechanical strength at day 1 post injury compared with that of the ST2−/− mice. These data suggest 
altered collagen matrix synthesis in ST2−/− mice implicating IL-33/ST2 as an early modulator of 
collagen changes in tendon injury that has biomechanical significance. Taken together these studies 
demonstrate a key functional role for IL-33/ST2 in early injury induced matrix dysregulation and 
subsequent cytokine feedback mechanisms (Figure 2) that have an ultimate biomechanical and 
clinical effect[61].   
Factors regulating the IL-33/ST2 axis continue to be elucidated. Caspases-3 and -7 inactivate IL-33 by 
cleaving its C-terminal IL-1 domain [63]. This inactivation event is believed to ensure specific roles 
of IL-33 in pathogenic situations such as parasitic infection, but not in non-inflammatory 
physiological situations, such as apoptosis. Invading pathogens mediate tissue damage leading to 
necrosis of barrier cells and this non- programmed cell death results in IL-33 release in the absence of 
inactivation by caspases-3 and -7. Others have found that the transcriptional regulators IRF4 and 
BATF cooperate at the Il1rl1 locus to induce the expression of ST2 [64]. Additionally, proteases 
mainly secreted by neutrophils seem to play an active role. Calpain, cathepsin G, elastase and 
proteinase cleave pro-IL-33 and remove the N-terminal domain, leaving the mature form of IL-33 
with a ten-fold higher affinity to its receptor [65] [33]. Emerging studies highlight miRNAs as key 
regulators of leukocyte function and the cytokine network while orchestrating proliferation and 
differentiation of stromal lineages that determine extracellular matrix composition [66]. Having 
established that IL-33 drives the differential regulation of collagen 1 and 3 in tenocytes, we postulated 
a mechanistic role for the miRNA network in this process. Previous studies have shown that the miR-
29 family directly targets numerous extracellular matrix genes [65] and is implicated in the regulation 
of innate and adaptive immunity [66]. All members of the miR-29 family were expressed in human 
tendon biopsies and explanted tenocytes with miR-29a showing the most altered expression in early 
tendinopathy biopsies. In tenocyte culture, IL-33 significantly reduced the expression of miR-29a, in 
an NF-κB, dependent manner [61]. miR-29a manipulation selectively regulated collagen 3 but not 
collagen 1 mRNA and protein expression in primary tenocytes. Moreover, miR-29a overexpression 
significantly decreased IL-33-induced collagen 3 mRNA and protein synthesis. In addition, miR-29a 
inhibition resulted in a significant increase in COL 3A1 expression, indicating that miR-29a is not 
only actively regulating these transcripts in human tenocytes but its loss can be an important factor in 
the increase of type 3 collagen production observed in tendinopathy [61]. In contrast, COL 1A1 and 
A2 transcript levels were relatively unchanged. Soluble ST2 message was significantly decreased by 
transfection with miR-29a mimic and increased by antagomir with a corresponding significant change 
in soluble ST2 protein confirming soluble ST2 as a target of miR-29a. Thus, IL-33-driven loss of 
miR-29a expression resulted in the simultaneous repression of collagen 3 and sST2, with a subsequent 
autoregulatory inhibition of IL-33 promoting the resolution of the immediate alarmin response [61]. 
The discovery of a single miRNA-dependent regulatory pathway in early tissue damage events 
highlights miR-29a replacement therapy as a promising therapeutic option for tendinopathy with 
implications for other human pathologies in which matrix dysregulation is implicated. The recent 
initiation of a Phase 1 clinical study of MRG-201, a synthetic microRNA mimic to microRNA-29b 
with possible extension to patients suffering from cutaneous scleroderma may therefore lead to future 
microRNA therapies in damage associated pathologies [67]. 
Given this role for IL-33 in tendons and the link between tendons and muscle it is interesting that a 
recent role for IL-33 in repair of skeletal muscle has also been shown. Normal repair of skeletal 
muscle requires expansion of local Treg cells. Using elegant studies in both aged and normal mice, 
Kuswanto and colleagues demonstrated that IL-33 regulates muscle Treg homeostasis in young mice 
and that a reduction of IL-33 in aged mice is associated with reduced skeletal muscle repair and 
regeneration. Administration of IL-33 in aged mice was associated with marked improvement in 
muscle Treg accumulation and muscle regeneration [68]. As defective muscle repair subsequent to 
injury and atrophy is a major health problem associated with aging populations, it is possible, 
therefore, that activation of the IL-33/ST2 axis is a potential therapeutic area in this field.   
The mechanics of wound healing: a role for IL-33 in angiogenesis  
Angiogenesis is critical to wound repair. Newly formed blood vessels participate in provisional 
granulation tissue formation and provide nutrition and oxygen to growing tissues. Angiogenesis, in 
response to tissue injury, is a dynamic process that is highly regulated by signals from both serum and 
the surrounding extracellular matrix (ECM) environment. Some cytokines implicated in inflammation 
have been shown to induce angiogenesis and increase vascular permeability and as such play a key 
role in regulating inflammatory angiogenesis. Given the role of IL-33 in promoting wound healing in 
response to both disease and trauma-induced tissue damage, it is therefore perhaps unsurprising that 
clear evidence has been presented to show that IL-33/ST2 can directly drive angiogenesis. IL-33 is 
strongly expressed in endothelial cells (EC), with IL-33 promoting proliferation, migration and 
morphological differentiation of EC [69]. In addition, IL-33 promotes angiogenesis, increases 
vascular permeability, and induces activation of endothelial cells toward an inflammatory phenotype 
through upregulation of IL-6, IL-8, monocyte chemoattractant protein-1, vascular cell 
adhesionmolecule-1, intercellular adhesion molecule-1, and endothelial selectin [70] [71, 72]. IL-33 
has also been shown to increase the production of urokinase-type plasminogen activator (u-PA) in EC 
[73]. u-PA has been implicated in a variety of angiogenesis-dependent physiological as well as 
pathological events such as wound healing. Furthermore, IL-33 drives upregulation of Tissue Factor 
(TF) in ECs [74].  As TF is the primary trigger of coagulation, this further highlights the importance 
of IL-33 in the early stages of wound healing.   
The findings above on the role of IL-33 in angiogenesis focus on the presence of extracellular IL-33 
in tissues, and therefore on IL-33 functioning in its capacity as an alarmin. IL-33, however, is 
abundantly expressed in the nuclei of endothelial cells in most healthy human tissues with nuclear IL-
33 observed to disappear rapidly from blood vessels on tissue injury and in lesions of acute 
inflammation [5].  In the context of wound-healing and wounding, it was noted that nuclear IL-33 was 
lost from all vessels close to the wound as early as 24 hours after injury with nuclear IL-33 remaining 
absent during wound-healing angiogenesis.  Endothelial nuclear IL-33 expression was shown to be 
regulated by Notch signalling [75]. Thus, release of IL-33 appears to be a feature of activated 
endothelial cells, whereas nuclear IL-33 expression is related to a state of vascular quiescence with 
nuclear IL-33 potentially repressing angiogenesis and therefore supressing wound healing. The 
complexity of IL-33 biology is such that further examining the transcriptional repressor activity and 
other nuclear functions of IL-33 in endothelial cells is of high importance to fully understand the role 
of this protein in wound-healing angiogenesis. 
Uncontrolled wound healing responses: The role of IL-33 in fibrosis 
Chronic inflammation and uncontrolled wound repair mechanisms, including unrestrained 
myofibroblast differentiation, fibroblast activation and excessive collagen deposition can lead to 
fibrosis. The associated, often irreversible, impaired organ function is classified as fibrotic disease, a 
leading cause of human mortality and morbidity. Identifying key underlying mechanisms of fibrosis is 
of the utmost importance for the development of novel therapies to treat this wide-ranging disease. 
Recently, the IL-33/ST2 pathway has been implicated in a plethora of fibrotic diseases with beneficial 
effects being reported in some, whilst adverse effects have been noted in other systems, with these 
being recently reviewed in some detail [76] [77].  
Pro-fibrotic roles for IL-33 and ST2 have been reported in the liver, GI, lung, skin and kidney [76]. 
IL-33 is elevated in patients with idiopathic pulmonary fibrosis (IPF) as well as in the bleomycin-
induced murine model of lung injury and fibrosis. This was observed to be predominantly full-length 
intra-nuclear IL-33 (flIL-33). Combined flIL-33 and bleomycin exerted a synergistic effect on 
pulmonary fibrosis. Interestingly, this effect was still observed in ST2 knockout mice, implying that 
this response may be mediated by nuclear located flIL-33 effecting gene expression [78]. In contrast 
Li et al demonstrated that both ST2 deficiency and administration of a blocking IL-33 antibody was 
able to attenuate bleomycin-induced pulmonary fibrosis [79]. Furthermore, intranasal administration 
of lentiviral expressing soluble ST2 significantly attenuated pulmonary fibrotic change and improved 
survival rate [80]. A variety of studies have revealed that IL-33 overexpression is implicated in the 
development of cutaneous fibrotic diseases, such as cutaneous fibrosis [81], psoriasis [82], and 
progressive systemic sclerosis [83]. To model chronic IL-33 release caused by sustained tissue 
damage, repeated administration of rhIL-33 revealed that it induces ST2- dependent cutaneous 
fibrosis and inflammation. Moreover it was noted that IL-13 is a critical downstream mediator of IL-
33-induced cutaneous fibrosis requiring eosinophils and RAG-dependent lymphocytes [81]. A direct 
correlation between both IL-33 and ST2 levels has been observed in both mouse and human liver 
fibrosis correlating closely with collagen expression, again highlighting a role for IL-33/ST2 in 
regulation of matrix proteins [84]. IL-33 has been shown to directly promote hepatic fibrosis, at least 
in part, through its ability to recruit and activate liver-resident ILC2s [85]. IL-33 has also been shown 
to be elevated in biliary atresia patient serum and in the livers and bile ducts of mice with 
experimental biliary atresia. Injury to the biliary epithelium triggers inflammation and can result in 
both intra- and extra- hepatic fibrosis. Administration of IL-33 markedly increased cholangiocyte 
proliferation and promoted sustained cell growth, resulting in dramatic and rapid enlargement of 
extrahepatic bile ducts. This increased proliferation was mediated by an increase in the ILC2 
population [86]. 
Extensive research has detailed an increase in expression of sST2 as early as 1 day after myocardial 
infarction (MI) and with this increase correlating with the ongoing process of cardiac inflammation, 
and fibrosis. Indeed, levels of sST2 are a good predictor of clinical outcome following MI, with high 
levels correlating with a poor prediction and lower levels correlating with a more favorable prognosis 
[87]. As sST2 is a negative regulator of IL-33 signaling, it is not surprising therefore, that a critical 
role of IL-33 in regulating cardiac myocyte activities and a protective role for IL-33 in cardiac fibrotic 
diseases have been suggested. It was demonstrated that IL-33 inhibits cardiomyocyte apoptosis both 
in vitro and in vivo and that IL-33 improved cardiac contractile function after ischemia/reperfusion 
myocardial injury in rats [88].  In addition, in vivo administration of IL-33 significantly decreased 
cardiac interstitial fibrosis in wild type mice that had undergone transaortic constriction surgery to 
increase cardiovascular load [89]. Cardiac fibroblasts, themselves, express ST2 and respond to IL-33 
by inducing pro-inflammatory cytokines and chemokines IL-6 and MCP-1[90]. A similar protective 
function for IL-33 and ST2 has also been observed in atherosclerosis, a fibrosing disease of the 
arteries.  Indeed, it is proposed that low levels of IL-33 may predispose to the development of 
atherosclerotic plaques [91]. Clearly, therefore this important signaling pathway exerts notably 
divergent effects in varying types of fibrosis and as such further work is required to fully understand 
these roles before the therapeutic potential of this pathway can be fully exploited.  
“Wounds that do not heal” – Understanding the role of IL-33 in tumorigenesis 
Wound healing and cancer progression have striking similarities. In 1986, Harold Dvorak suggested 
that “tumours are wounds that do not heal” [92].  His observations were that the mechanisms of 
wound healing and the formation of tumour stroma had similar connective tissue components, 
including fibroblasts, blood and lymphatic vessels, inflammatory cells, and extracellular matrix. In 
contrast to healing wounds, chronicity of the inflammatory phase results in uncontrolled cell 
proliferation, invasion, and metastasis. As outlined above, the IL-33/ST2 pathway participates in 
many of these processes, demonstrating clear direct effects on angiogenesis, production of matrix 
components, on fibrosis that can lead to tumour formation, and on modulation of immune populations 
which can therefore affect the tumor microenvironment. Unsurprisingly, therefore, links between the 
IL-33/ST2 signalling axis and tumorigenesis have recently been identified. In a parallel manner to the 
divergent roles of IL-33/ST2 reported in many of the processes associated with wound healing, both 
pro- and anti-tumorigenic roles have been reported for IL-33 and ST2 in cancer. 
Initially the link between IL-33/ST2 and cancer was identified in breast cancer. Early studies utilising 
ST2-/- mice demonstrated that ST2 deletion inhibited breast cancer progression and increased the 
intra-tumoral accumulation of both innate (NK cell) and acquired immunity (CD8+ T-cells) and 
Th1/Th17 cytokines, indicating that a lack of IL-33 signalling through ST2L promotes a Th1 response 
21484786. In addition, suppressing sST2 reduced ErbB2-induced cell motility in breast cancer cells. 
Furthermore, breast cancer patients with metastatic disease showed increased levels of circulating 
sST2 compared to patients with primary tumours [93]. Further studies in breast cancer also showed 
significantly higher levels of both IL-33 and sST2 in the serum of patients with ER positive breast 
cancer relative to healthy controls [94]. In a subsequent study, administration of IL-33 to breast 
cancer-bearing mice accelerates tumour growth and increased metastasis. The proposed mechanism 
responsible for the enhanced tumour growth was the increase in the number of infiltrating 
immunosuppressive immune cells and innate lymphoid cells, providing further evidence of the role of 
IL-33 in driving carcinogenesis [95]. Consistent with a role for IL-33 and ST2 in promoting tumour 
metastasis and invasion, inhibition of IL-33 and ST2 in glioma cells resulted in reduced tumour 
growth and colony formation in vitro, and reduced tumour size in vivo [96]. In head and neck 
squamous cell carcinoma (HNSCC), it has been shown that administration of IL-33 promoted cancer 
cell migration and invasion through induction of epithelial-mesenchymal transition [97]. Recently, it 
has been suggested that IL-33 can promote gastric cancer cell invasion and migration, which was 
suggested to be mediated by activation of ERK1/2 [98]. In this study, ST2-/- mice showed attenuated 
IL-33-mediated invasion and migration of cancer cells. In squamous cell carcinoma of the tongue, IL-
33 and ST2 were shown to be expressed in cancerous cells in 100% of cases examined and cases with 
higher protein expression of IL-33 and ST2 showed poor overall survival [99]. More recently elegant 
work by Akimoto et al, investigating the role of IL-33 and ST2 in lung demonstrated that IL-33 
enhanced the cell death of ST2L-positive low-metastatic cells, but not of ST2L-negative high-
metastatic cells. These authors concluded that IL-33 enhances lung cancer progression by selecting 
for more malignant cells in the tumour microenvironment [100].  Finally several recent reports have 
reported a pro-tumorigenic role for IL-33 in colon cancer [101, 102] [103, 104]. These studies 
reported an increase in IL-33 in colorectal cancer as compared to adjacent normal tissue and healthy 
volunteers, with IL-33 having a protective anti-tumourigenic effect in colorectal cancer. Inhibition of 
IL-33 in colon cancer cells resulted in reduced tumour growth, migration and colony formation in 
vitro, and smaller tumours in vivo [102]. IL-33 was also shown to activate tumour stroma and 
promote polyposis in APC(Min/+) mice [103]. 
Other studies, however, have shown divergent anti-tumorigenic effects of IL-33 and ST2 in cancer. 
Levels of IL-33 have been reported to be reduced in the plasma of non-small cell lung cancer patients 
relative to controls [105], and levels of IL-33 have also been shown to negatively correlate with 
tumour stage in multiple myeloma patients [106]. Interestingly, IL-33 has been observed to be 
increased in response to viral infection and to be important for the eradication of a viral insult, as it 
can differentiate CTLs into anti-viral CD8+ T cells [107]. IL-33 has also been shown to synergize with 
IL-12 to promote CD8+ T cell effector function [108]. In line with the ability of IL-33 to promote a 
CD8+ T cell response and the fact that CD8+ T cells mediate a vital role in the defence against cancer, 
over-expression of IL-33 potently inhibited tumour growth and metastasis in both B16 melanoma and 
4T1 breast cancer models with both CD8+ T cell and NK cell numbers seen to be increased [109]. 
Similarly, transgenic expression of IL-33 reduced tumour metastasis in a Lewis lung carcinoma and 
B16 melanoma model. Both the number and the cytotoxicity of CD8+ T cells and NK cells were 
increased in response to IL-33 expression [110]. In contrast to the above finding detailed concerning a 
pro-tumorigenic role for IL-33 in CRC, we recently demonstrated that the IL-33/ST2 axis plays an 
anti-tumorigenic role in colon cancer as ST2L expression is decreased in human colon cancer tissue as 
compared to adjacent non-tumour tissue, with lower ST2L expression correlating with poorer patient 
prognosis. Consistent with this, knockdown of ST2 in murine colon cancer cells, resulted in enhanced 
tumour growth (p<0.05) in vivo with reduced CD8+ T cell infiltration observed in the ST2L 
knockdown tumours as compared to the control tumours [29]. 
It appears therefore, that the role of both IL-33 and ST2 in tumorigeneisis may be defined by the 
tumour type and source of the tumour. However, the models utilised above often differ in terms of 
reducing expression of these proteins either within the tumour or within the tumour 
microenvironment. These differing approaches appear to be in part responsible for the seeming 
divergent roles of these proteins in tumorigenesis.  
Conclusions: 
In certain tissue microenvironments the IL-33/ST2 axis appears to have a role in the immediate tissue 
response to injury in keeping with its „alarmin‟ function while additionally regulating matrix 
homeostasis via immune cell crosstalk. It is equally clear, however, that divergent roles in wound 
healing, angiogenesis, fibrosis and tumorigenesis have also been ascribed to both IL-33 and ST2. 
Thus while manipulation of the IL-33/ST2 pathway represents a promising new therapeutic strategy 
for targeting damage associated tissue repair further mechanistic elucidation of its biology is required. 
Whilst some of these divergent roles can potentially be explained as a tissue/cell type specific 
function, it seems likely that a greater understanding of the biology and regulation of IL-33, in 
particular dissecting the conflicting roles of intracellular versus extracellular IL-33 may shed much 
needed light on the biological functions of the IL-33/ST2 axis and its role in wound healing, fibrosis 
and cancer.  
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Figure Legends 
Figure 1: The IL-33/ST2 signalling pathway. 
In humans three splice variants of ST2 exist: ST2L, sST2 and ST2V. sST2 is a soluble protein with no 
transmembrane sequence, it is excreted extracellularly and binds to IL-33. sST2 is thought to act as a 
decoy receptor sequestering IL-33 away from the transmembrane bound receptor ST2L. ST2V is a 
membrane-bound receptor that contains a hydrophobic tail. It contains two Ig domains and is 
expressed in the gut, the function of ST2V has not been fully elucidated. IL-33 binds to the ST2L 
receptor and once IL-1RAcP is recruited, the TIR  domain of IL-1RAcP interacts with the ST2L TIR 
domain. The heterodimeric complex acts as a scaffold for the recruitment of MyD88, IRAK-1 and 
IRAK4. This results in the phosphorylation of B which activates the transcription factor NF-𝜅B. 
AP-1 has also been shown to be activated through activation of the MAPK signalling pathway. This 
activates a pro-inflammatory response via the induction of cytokines and chemokines. 
 
 
Figure 2 
The role of the IL-33/ST2 axis in the immediate tissue response to injury – lessons from tendon 
Schematic depicting the IL-33/ST2 signaling in tendon disease, representing tissue microtrauma.  
Tissue injury/stress results in the release of IL-33 which acts to both promote immune cell recruitment 
/enhanced cytokine production (IL-6, IL-8, CCL-2) and matrix remodeling via the ST2/IL-1RaCP 
complex and subsequent repression of microRNA29a. The IL-33-driven loss of miR-29a expression 
results in the simultaneous repression of collagen 3 and sST2, with a subsequent autoregulatory 
inhibition of IL-33 promoting the resolution of the immediate alarmin response. The tissue 
microenvironment subsequently displays an inflammatory phenotype compared to the homeostatic 
tendon. The resultant crosstalk between IL-33/ST2 and matrix proteins determines resolution versus 
pro damage pathways reflecting in clinical disease. 
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